Related references
Note: Only part of the references are listed.Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states
Feng Wen et al.
LIVER INTERNATIONAL (2021)
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
Dan Su et al.
JAMA NETWORK OPEN (2021)
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren et al.
LANCET ONCOLOGY (2021)
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis
John J. Kim et al.
ONCOLOGIST (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Shugeng Gao et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
Hongfu Cai et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
Masnoon Saiyed et al.
CLINICAL DRUG INVESTIGATION (2020)
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Masahiro Kobayashi et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Expenditure of hospital care on cancer in China, from 2011 to 2015
Yue Cai et al.
CHINESE JOURNAL OF CANCER RESEARCH (2017)
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
Alessandro Granito et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis
Pengfei Zhang et al.
DIGESTIVE AND LIVER DISEASE (2016)
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
Pengfei Zhang et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
Claudia Allemani et al.
LANCET (2015)
The impact of hospice care on survival and cost saving among patients with liver cancer: a national longitudinal population-based study in Taiwan
Jui-Kun Chiang et al.
SUPPORTIVE CARE IN CANCER (2015)
Health state utilities for metastatic breast cancer
A. Lloyd et al.
BRITISH JOURNAL OF CANCER (2006)
Share Paper
